Drug Trial Radar · NCT07644039
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
119
Planned (sponsor's estimate)
Start
May 21, 2026
Primary completion
Apr 2, 2029
Study completion Apr 2, 2029
Sponsor
- Lead sponsor
- PharmaMarIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator's assessment in participants in other cohorts.
Conditions
- Advanced Malignancies
Interventions
PembrolizumabDrug
Intravenous infusion.
PM54Drug
Intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Treatment DiscontinuationTime frame: From signing of the informed consent up to 30 days after last dose (up to 3 years)
- Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (each cycle is of 21 days)
- Part 2: Clinical Benefit RateTime frame: up to 12 weeks
- Part 2: Objective Response RateTime frame: Baseline up to 3 years
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
START New York
New York, New York · Recruiting
START Dallas
Fort Worth, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Houston
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Institut Català d'Oncologia (ICO) - Hospital Durans i Reynals.
Barcelona, Spain · Recruiting
Clinica Universidad de Navarra (CUN)
Madrid, Spain · Recruiting
Hospital General Universitario Gregorio Marañón
Madrid, Spain · Recruiting
START Madrid - Hospital Universitario Fundacion Jimenez D
Madrid, Spain · Recruiting
Clinica Universidad de Navarra (CUN)
Pamplona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.